Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $39.72M (cash outflow) rose 128.9% year over year, ahead of the -770.3% change in trailing-twelve-month net income. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Net income amounted to 565.5% of revenue in FY2025, up 534.3 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$166.79M (+16.0%) for the fiscal year ending Dec 2026, a step up from the -319.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$39.72M+1.4% QoQ
Last fiscal yearDec 2025
-$143.75M-319.0% YoY
LTMMar 2026
-$166.12M-770.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+128.9%+3.2%-125.8 pp
1 year-319.0%+16.0%+335.1 pp
3-year CAGR+15.0%+13.7%-1.3 pp
5-year CAGR-4.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(143.75M) USD
Year-over-year change
-319.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 net income of $166.12M is the 5th largest of the 11 companies compared; the peer median is $107.11M.
  • Its year-over-year change of -770.3% is the lowest of 11, against a peer median of +18.4%.
  • Net income amounts to 2895.1% of revenue for TRDA, versus a peer median of 246.5%.
TRDA Competitors Peer median
Net Income for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B +146477.0%+53.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M -31.1%-16.9%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M +21.5%+11.0%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M -770.3%+15.0%2895.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
IMRXImmuneering CorporationLTM Mar 2026$54.44M -11.9%+3.5%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M +12.6%+8.9%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$43.51M -23.8%+18.7%—
Peer median (excluding TRDA) $107.11M+18.4%+14.8%246.5%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Depreciation & Amortization1.12M1.9M2.84M3.77M4.1M
Deferred Income Tax00000
Stock-Based Compensation2.53M9.9M13.11M17.92M19.61M
Change in Working Capital(3.42M)(11.11M)136.32M(118.85M)(4.8M)
Accounts Receivables0002.2M2.5M
Inventory00000
Accounts Payables(715K)5.29M(2.81M)991K(1.8M)
Other Working Capital(2.71M)(16.4M)139.12M(122.04M)(5.5M)
Other Non-Cash Items74K151K(5.78M)(10.02M)(3.67M)
Operating Cash Flow(50.86M)(93.79M)139.8M(41.56M)(128.51M)
Capital Expenditures(4.58M)(2.89M)(5.61M)(3.16M)(1.04M)
Acquisitions (Net)00000
Purchases of Investments0(221.98M)(407.21M)(437.72M)(141.61M)
Sales of Investments076.21M274.43M413.08M259.46M
Other Investing Activities00000
Investing Cash Flow(4.58M)(148.65M)(138.4M)(27.8M)116.81M
Debt Repayment00000
Common Stock Issued190.69M479K19.41M99.61M887K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities939K01.63M3.36M0
Financing Cash Flow307.46M479K21.04M102.96M887K
Effect of Forex Changes0(3.95M)000
Net Change in Cash252.02M(245.91M)22.45M33.61M(10.82M)
Free Cash Flow(55.44M)(96.67M)134.19M(44.72M)(129.55M)

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.